Compare MCW & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCW | AUPH |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2021 | 2014 |
| Metric | MCW | AUPH |
|---|---|---|
| Price | $7.10 | $15.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $7.28 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.62 | ★ 5075.00 |
| EPS | 0.10 | ★ 0.25 |
| Revenue | ★ $1,051,731,000.00 | $283,055,000.00 |
| Revenue This Year | $7.92 | $17.54 |
| Revenue Next Year | $7.05 | $15.74 |
| P/E Ratio | $70.89 | ★ $63.38 |
| Revenue Growth | 5.73 | ★ 20.38 |
| 52 Week Low | $4.61 | $7.29 |
| 52 Week High | $7.69 | $16.88 |
| Indicator | MCW | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 45.49 |
| Support Level | $6.95 | $14.53 |
| Resistance Level | $7.14 | $16.38 |
| Average True Range (ATR) | 0.04 | 0.66 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 58.62 | 39.80 |
Mister Car Wash Inc is a car wash brand offering express exterior and interior cleaning services. The company's car wash locations consist of two formats: Express Exterior Locations and Interior Cleaning Locations. Express Exterior Locations offer self-drive exterior cleaning services and include free vacuums available for customer use. Interior Cleaning Locations offer exterior and interior cleaning services, including vacuuming. The company recognizes revenue from activities related to providing car wash services at its car wash locations that are geographically diversified throughout the United States and have similar economic characteristics and nature of services.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.